Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Today Michigan.
Press releases published on June 25, 2025
SmartVascular Dx™ Test: Enhancing Vascular Care in the Midwest
GlobeNewswire
·
June 25, 2025
IRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC., (“MSL” or “the Company”), is a leading developer of precision diagnostic tests that address unmet clinical needs, is proud to announce its expansion in the Midwest with the …
First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial
GlobeNewswire
·
June 25, 2025
The first CLARITY patient was enrolled at the Texas Back Institute, a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to demonstrate Nociscan’s ability to improve …
Global Juice Testing Industry on Track for Robust 8.2% CAGR Growth | Europe Leads the Way in Juice Testing Standards and Compliance
GlobeNewswire
·
June 25, 2025
Delray Beach, FL, June 25, 2025 (GLOBE NEWSWIRE) -- The juice testing market size is on an upward trajectory, expected to rise from USD 0.86 billion in 2025 to USD 1.28 billion by 2030, at a CAGR of 8.2%. This growth is fueled by rising health awareness, …
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
GlobeNewswire
·
June 25, 2025
REYKJAVIK, Iceland and PISCATAWAY, N.J. and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC …
Actimed Therapeutics Enrolls First Patients in Phase 2a PROACT Study Programme to Assess S-pindolol benzoate in Obese Patients During and Post-GLP-1 Agonist Therapy
GlobeNewswire
·
June 25, 2025
Two-part clinical study programme to evaluate change in lean and fat mass in patients receiving two different doses of S-pindolol benzoate whilst 1) receiving the GLP-1 agonist semaglutide; and 2) after cessation of semaglutide treatment Initial proof-of- …
Essential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive Director
GlobeNewswire
·
June 25, 2025
Essential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive Director Egham, UK – 25 June 2025 – Essential Pharma (“Essential” or “the Company”), a global pharmaceutical company developing and delivering medicines for patients …
Führendes Unternehmen für Access Management für das Gesundheitswesen und andere kritischen Branchen verstärkt Engagement in Deutschland, Österreich und der Schweiz
GlobeNewswire
·
June 25, 2025
LANGENFELD, Deutschland, June 25, 2025 (GLOBE NEWSWIRE) -- Mit der Besetzung von zwei neuen Stellen unterstreicht Imprivata, das führende Unternehmen für Access Management im Gesundheitswesen und anderen kritischen Branchen, sein Engagement in Deutschland, …
OSE Immunotherapeutics provides an update on ongoing proceedings
GlobeNewswire
·
June 25, 2025
OSE Immunotherapeutics provides an update on ongoing proceedings Nantes, June 25th, 2025, 8:00 a.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), announces that, following the hearing on June 24th, 2025, regarding the request to retract the …
OSE Immunotherapeutics met à jour l’information sur les procédures en cours
GlobeNewswire
·
June 25, 2025
OSE Immunotherapeutics met à jour l’information sur les procédures en cours NANTES, France, 25 juin 2025, 8 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) annonce qu’à la suite de l’audience le mardi 24 juin 2025, relative à la demande …
LIfT BioSciences Expands U.S. Footprint with New Facility at Portal Innovations, Houston Helix Park
GlobeNewswire
·
June 25, 2025
LIfT BioSciences Expands U.S. Footprint with New Facility at Portal Innovations, Houston Helix Park London, 25 June 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today …
Addex Shareholders Approve All Resolutions at Annual General Meeting
GlobeNewswire
·
June 25, 2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today …
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
GlobeNewswire
·
June 25, 2025
Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Ongoing phase 2 study evaluating riliprubart for the potential prevention and treatment of active antibody-mediated rejection in kidney …
Communiqué de presse : Le riliprubart est désigné comme médicament orphelin aux États-Unis pour le rejet induit par les anticorps dans la transplantation d’organes solides
GlobeNewswire
·
June 25, 2025
Le riliprubart est désigné comme médicament orphelin aux États-Unis pour le rejet induit par les anticorps dans la transplantation d’organes solides Étude de phase 2 en cours évaluant le riliprubart pour la prévention et le traitement potentiels du rejet …
Tilray Medical erhält vom italienischen Gesundheitsministerium die erste Genehmigung für den Vertrieb von medizinischen Cannabisblüten für therapeutische Zwecke
GlobeNewswire
·
June 25, 2025
SAVONA, Italien, June 25, 2025 (GLOBE NEWSWIRE) -- Tilray Medical („Tilray“), ein Geschäftsbereich von Tilray Brands, Inc. (NASDAQ: TLRY und TSX: TLRY) und weltweit führender Anbieter von medizinischem Cannabis, der die therapeutische Zusammenarbeit …
Une première autorisation de distribution de la fleur de cannabis médicinal à des fins thérapeutiques délivrée par le ministère de la Santé italien pour Tilray Medical
GlobeNewswire
·
June 25, 2025
SAVONE, Italie, 25 juin 2025 (GLOBE NEWSWIRE) -- Tilray Medical, ci-après « Tilray », une division de Tilray Brands, Inc. (NASDAQ : TLRY et TSX : TLRY) et un leader mondial du cannabis thérapeutique permettant aux patients comme aux professionnels de santé …
Cidara Announces Pricing of Upsized Public Offering of Common Stock
GlobeNewswire
·
June 25, 2025
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the pricing of an …